2009
DOI: 10.1684/ejd.2009.0654
|View full text |Cite
|
Sign up to set email alerts
|

Vesicular Sézary syndrome with bullous lesions on the feet

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
1
2
0
Order By: Relevance
“…Bullous Sézary syndrome is even rarer with fewer than 10 cases reported. Bullous lesions may arise in existing lesions of CTCL or as the initial presentation, may be associated with patch, plaque, or tumoral lesions and display a predilection for the torso and extremities [2,[4][5][6][7][8][9][10][11]. Oral mucosal involvement was present in our patient and has been described in one other case of bullous Sézary syndrome [9].…”
Section: Case Discussionsupporting
confidence: 56%
See 1 more Smart Citation
“…Bullous Sézary syndrome is even rarer with fewer than 10 cases reported. Bullous lesions may arise in existing lesions of CTCL or as the initial presentation, may be associated with patch, plaque, or tumoral lesions and display a predilection for the torso and extremities [2,[4][5][6][7][8][9][10][11]. Oral mucosal involvement was present in our patient and has been described in one other case of bullous Sézary syndrome [9].…”
Section: Case Discussionsupporting
confidence: 56%
“…In patients with bullous mycosis fungoides, approximately 50% died within one year of presentation [2,13]. Of the reported cases of bullous Sézary syndrome, two patients passed away within one year of presentation and one patient was in remission at 15 months although longer term followup was not reported [9][10][11]. This parallels the disease…”
Section: Case Discussionmentioning
confidence: 99%
“…Most studies are small case reports with inconsistent dosing regimens, intervals, and duration of treatment, and a variety of adjunctive therapies (Table I). In addition, the rates of complete response, partial response, stable disease, and disease progression have been highly inconsistent, ranging from no response or progression in 75% of patients 10 to a complete response of 96% of lesions 11. With such varied responses in outcome, and with a treatment option that appears to be associated with minimal morbidity, our purpose was to document the response of in‐transit metastases to intra‐lesional IL‐2 injection using a consistent regimen in a large series of consecutive patients.…”
Section: Introductionmentioning
confidence: 99%